Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00ANG
|
|||
| Former ID |
DIB014887
|
|||
| Drug Name |
Erythropoietin-transfected autologous cell therapy
|
|||
| Synonyms |
Epodure; Erythropoietin-transfected autologous cell therapy (Biopump); Erythropoietin-transfected autologous cell therapy (Biopump), Medgenics
Click to Show/Hide
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Phase 1/2 | [1] | |
| Company |
Medgenics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erythropoietin (EPO) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Signaling events mediated by Stem cell factor receptor (c-Kit) | ||||
| EPO signaling pathway | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| WikiPathways | EPO Receptor Signaling | |||
| Hematopoietic Stem Cell Differentiation | ||||
| Differentiation Pathway | ||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00542568) Safety and Efficacy of Sustained Erythropoietin Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.